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Abstract
The human version of the DPY-30 protein is homologous to the DPY-30
protein in Caenorhabditis elegans (nematode), along with other DPY-30
homologous proteins in other organisms. This protein is involved in dosage
compensation of X-linked genes, balancing the levels of expression of these
genes between the sexes. The mechanism by which the balancing is carried out
varies from organism to organism. For example, in C. elegans hermaphrodites
(XX), transcript levels of the X-linked genes are cut in half. In Drosophila, the
genes on the male’s (XY) X chromosome are transcribed at twice the rate of the
female’s (XX) genes. In human females (XX), one of the X chromosomes in each
cell is inactivated at random. If DPY-30 is absent from the organism, this can
lead to XX-lethality. In humans, DPY-30 forms a complex with four other
proteins: MLL1, WDR5, RbBP5, and ASH2L. This complex is responsible for
methylating histones, particularly histone H3 Lysine 4 (H3K4). Methylation of
H3K4 promotes transcription of genes. Similar complexes are found in other
organisms. The fact that these proteins are conserved across species indicates
how important they are. Within the complex itself, DPY-30 binds to ASH2L. The
amino acids responsible for this interaction, however, remain unknown. The
purpose of this project is to identify which amino acids are responsible for the
binding between DPY-30 and ASH2L. A further extension of this project is its
potential anticancer applications. When MLL1 is activated improperly and forms
the complex, it can lead to the development of Acute Lymphoblastic Leukemia
(ALL). It is thought that if the complex were to be disrupted and broken apart or
prevented from forming, the cancerous cell would stop proliferating and die. If
the amino acids responsible for the DPY-30 and ASH2L binding were identified, a
drug or peptide could be designed to bind to DPY-30 or ASH2L, preventing it
from completing formation of the MLL1 Core Complex.
The first step in this experiment was to compare DPY-30 homologs from
different species, to see if any amino acid residues were either completely
conserved or mostly conserved. Once the conserved residues were identified,
one was selected to change, Arginine (R) 54. It was changed to an Alanine (A).
Three other single amino acid mutations were made: Arginine (R) 76, Leucine (L)
66, and Leucine (L) 65. All three were changed to Alanines. Once primers with
the correct mutation were made, the DNA sequence was put through PCR and
transformed into E. coli cells. The DNA was extracted, sequenced, and
transformed into another E. coli strain. A large culture was grown, expression of
protein was induced, the cells were lysed, and the protein was collected. Once
the mutant protein was purified, it was subjected to multiple tests to determine
its binding affinity for ASH2L. For the R54A mutant, the binding interactions
were weakened, but not completely inhibited. For the L66A mutant, there was
no measurable effect on the binding interactions. It was concluded that Arginine
54 was a much more important residue than Leucine 66, as far as binding affinity
was concerned.
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Capstone Project Body
Introduction
Human DPY-30 (dumpy-30) is a homolog of DPY-30 found in
Caenorhabditis elegans. It is found in the nucleus and is expressed in all human
tissues. DPY-30 is about 22.4 kiloDaltons (kD) and is a homodimer (Wang et al,
2009). The two identical monomers are each made up of two helical subunits
(Wang et al, 2009). This protein earned its name from experiments in which
mutations in the protein resulted in a “dumpy” phenotype in the organism, in
this case C. elegans (Hsu and Meyer, 1994). The human version of the protein is
a vital component of dosage compensation machinery and loss of DPY-30 activity
results specifically in XX-lethality (Dong et al, 2005). Dosage compensation is a
regulatory process that functions at the chromosome level to balance the levels
of expression of X-linked genes between the sexes (Hsu et al, 1995). Otherwise,
the sex with multiple X chromosomes would receive a two-fold dose of the Xlinked genes compared to the other sex, which leads to XX-specific lethality
(Dong et al, 2005). This condition, for example, affects C. elegans
hermaphrodites (XX), Drosophila females (XX), and female mammals (XX) (Hsu et
al, 1995). Even though the end result is the same, regulation of these X-linked or
sex-linked genes, however, is carried out differently from one species to another.
In C. elegans, the transcript levels produced by each X chromosome in XX
hermaphrodites are halved to equal the transcript levels of the X in males (XO)
(Dong et al, 2005). In Drosophila, the X-linked genes in males (XY) are
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transcribed at twice the rate as the two X chromosomes in females (XX) (Dong et
al, 2005).
In female mammals (XX), one of the X chromosomes is randomly
inactivated so that the X-linked gene expression level matches that of the males
(XY) (Dong et al, 2005). This leads to the formation of Barr bodies. A Barr body
is the term used to describe the highly condensed, inactivated X chromosome,
which is unable to have any of its genes transcribed and/or expressed. In certain
animals, DPY-30 is used for other developmental processes: normal body size,
mating behavior, correct tail morphology, and coordinated movement (Hsu et al,
1995). The homolog of DPY-30 found in yeast functions as a member of the
histone 3 lysine 4 methylation complex, which is the key part of the epigenetic
transcriptional control mechanism (Dong et al, 2005). Epigenetics refers to any
heritable change in gene expression, meiotic and/or mitotic, that is not actually
coded for in the DNA sequence of an organism (Egger et al, 2004). In humans,
DPY-30 is able to form a complex with four other proteins, Mixed Lineage
Leukemia protein-1 (MLL1), ASH2L, WDR5, and RbBP5 (Crawford and Hess,
2006). ASH2L stands for absent, small, homeotic discs-2-like, WDR5 stands for
WD repeat protein-5, and RbBP5 stands for retinoblastoma-binding protein 5
(Patel et al, 2008). The MLL1 complex is necessary for methylation of histones,
in particular histone H3 Lysine 4 (H3K4) (Crawford and Hess, 2006). This
methylation is important for allowing transcription of target genes to occur
within cells (Crawford and Hess, 2006). MLL1 is also vital to the regulation of hox
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genes in hematopoiesis and development (Patel et al, 2008). The fact that these
core components are conserved across species speaks volumes about their
importance in cellular activity (Crawford and Hess, 2006). Within the MLL1 core
complex itself, DPY-30 binds specifically to ASH2L (South et al, 2009), yet the
identity of the binding site remains unknown (see Figure 1).

Figure 1: A cartoon model of the theoretical
structure of the MLL1 Core Complex. (Figure
obtained from Patel et al, June 25, 2009)
Another aspect of this project is its potential therapeutic applications.
The MLL1 gene itself has a tendency to undergo reciprocal translocations
(Srinivasan et al, 2004), where the gene breaks at a cleavage point and rejoins
with another gene from another chromosome. Another occurrence is that MLL1
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can undergo partial tandem duplications (MLL-PTD), where certain parts of the
gene are duplicated. Both situations result in fusion proteins, which have been
directly linked to leukemogenesis, specifically Acute Lymphoblastic Leukemia
(ALL) (Srinivasan et al, 2004). When functioning normally, MLL1 is critical for
hematopoiesis and the development of the organism, as the loss of function
results in death. The involvement of this protein in cancer is the ultimate driving
force behind this project. These MLL-PTD proteins still end up forming the
complex with the other four proteins. The idea is that if the formation of the
complex was disrupted, the cancerous cell would not be as active or as potent,
which would help in treating people with the disease. This is why discovering
the amino acids that make up the binding site between DPY-30 and ASH2L is so
important. A peptide or drug could then be used to block formation of the
complex. This same strategy could be employed with any of the other binding
sites within the complex.
The purpose of my research is to determine which amino acid residues
are involved in the binding process between the DPY-30 protein and the ASH2L
protein. A sequence alignment will be performed using various homologs of
DPY-30 in order to determine which residues have been conserved over the
course of evolution. Such homologs include the DPY-30 homolog in C. elegans
and the Saf19p protein, the DPY-30 homolog in S. cerevisiae (Dong et al, 2005).
The rationale behind this is that if certain residues have been completely or
mostly conserved, they must have some importance for the function of the
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protein and/or the overall survival of the cell/organism. Once these conserved
residues have been identified, wild type DPY-30 protein will be expressed and
purified. Then the conserved residues will be systematically mutated one at a
time, via site-directed mutagenesis. The mutant DPY-30 proteins will be purified
and an assay will be performed after each individual mutation to determine how
it affects the binding of DPY-30 to ASH2L. To yield qualitative results, Native
(agarose) gel assays will be performed to observe if binding is affected.
Analytical Ultracentrifugation (AUC) will be used to obtain quantitative results
regarding to the binding affinity the mutated DPY-30 has for ASH2L. Additional
analysis of the mutant might include an enzymatic activity assay to see what
effect the mutant protein has on the ability of the MLL1 Core Complex to
methylate H3K4. This project is expected to provide some insight into the
specific role that DPY-30 plays in the MLL1 core complex.

METHODS
Sequence Alignment and Protein Expression and Purification
DNA sequences of DPY-30 homologs/DPY-30-like proteins in 13 different
organisms were collected and compared using the National Center for
Biotechnology Information’s database (NCBI). A sequence alignment was
performed, using Clustal W (Clustal 2.0.8, 2008), to identify completely
conserved or highly conserved amino acid residues (see Figure 15, Appendix A).
The organisms used for the alignment were Caenorhabditis elegans (nematode)
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(Accession number: Q10661), Saccharmyces cerevisiae (Baker’s yeast)
(Accession number: NP_010757), Mus musculus (house mouse) (Accession
number: Q99LT0), Homo sapiens (human) (Accession number: Q9C005), Bos
taurus (cattle) (Accession number: AAI11635), Ornithorhynchus anatinus
(platypus) (Accession number: XP_001508793), Monodelphis domestica (gray
short-tailed opossum) (Accession number: XP_001371479), Gallus gallus (red
jungle fowl) (Accession number: XP_419530), Strongylocentrotus purpuratus
(purple urchin/purple sea urchin) (XP_001189793), Pan troglodytes
(chimpanzee) (Accession number: XP_001164263 and XP_00164291), Apis
mellifera (honey bee) (Accession number: XP_001120012), Macaca mulatta
(rhesus monkey) (Accession number: XP_001105547 and XP_001105621), and
Canis lupus familiaris (dog) (Accession number: XP_532923). The 54th amino
acid, Arginine, was chosen as the first target for site-directed mutagenesis. The
forward and reverse primers with the appropriate mutation were designed and
ordered. The primer sequences were amplified using Polymerase Chain Reaction
(PCR). The reaction mixtures were put on ice for 2 minutes to cool them below
37°C and then subjected to Dpn I restriction enzyme digestion to get rid of any
parental or nonmutated DNA. Each amplification reaction was incubated at 37°C
for 1 hour to allow for proper digestion. The mutated DNA was then
transformed into Escherichia coli DH5α cells, which were then incubated on
Lysogeny Broth (LB) agar plates. Once colonies were formed, the blue ones,
which represented successful transformations, were selected to use for growing
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an overnight 5mL culture in LB broth/media. Five microliters of 1000x
carbenicillin were added to each tube used and the tubes were incubated at
37°C in a shaker, making sure the cap was slightly loose to allow oxygen to reach
the cells. Only one colony was used for inoculating each tube. Once the cultures
were grown, a Miniprep was performed to lyse the cells and extract the DNA.
The DNA was stored at -20°C.
The concentration of each DNA sample was measured and a sample of
each DNA sequence, along with the T7 primer, was sent to be sequenced at
SUNY Upstate Medical University to check for sequence accuracy. Five
microliters of sample and one microliter of T7 primer (1 picomole/microliter)
were mixed in a PCR tube. Once it was confirmed that the site was successfully
mutated from an Arginine into an Alanine, while maintaining the wild-type
sequence throughout the rest of the DNA, the mutant DNA was then
transformed into the Rosetta 2 PlysS strain of E. coli. A small scale culture was
grown using Terrific Broth II (TBII, 50mL). Fifty microliters each of carbenicillin
(50mg/mL stock solution) and 1x-chloramphenicol (20mg/mL stock solution)
were added to the culture. Then 10mL from the small scale culture were used to
start a large scale (1L) culture. Expression of the protein was induced through
the addition 1 mL of Isopropyl β-D-1-thiogalactopyranoside (IPTG, 1M stock
solution). The large flasks were placed on a shaker and incubated at 37°C. Once
the proper levels of growth were achieved, the cultures were incubated at 4°C
for 1 hour. The cells were then centrifuged and stored as a pellet in the -80°C
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freezer, if necessary. The pellet was thawed, if necessary, and was broken open
using Lysis buffer and a Microfluidizer.

RESULTS
The mutant protein was collected and purified through a series of steps.
The first was a Nickel Affinity Chromatography column (see Figures 2 and 3).
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Figure 2: DPY-30 R54A His-trap Run 1. The R54A protein sample (lanes 1-8) after its
first nickel affinity chromatography run. There are a lot of impurities (other proteins)
present. The protein marker (PM) or ladder is a set of standards with known
molecular weights and is used as a reference point for other proteins run on the gel.
The crude extract (CE) is taken from the protein sample prior to purification.

This technique is also called a His-trap run because DPY-30 has a His-tag (six
histidines) attached to its N-terminus. This structure has an affinity for Nickel,
allowing the protein to bind to the column, trapping it there, while other
proteins were washed away. The fractions with the protein were collected and
run on an SDS polyacrylamide gel to check the protein’s purity. The gel was
stained (coomassie Stain, 30 seconds in microwave, 10 minutes on rocker) and
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Figure 3: DPY-30
30 L66A His
His-trap Run 1. The L66A protein sample
(lanes 1-13) after its first nickel affinity chromatography run.
Notice the large amount of impurities present.

then destained (Destain 11- 30 seconds in microwave, discard, Destain 22 30
seconds in microwave, overnight on rocker) to allow the bands to be viewed.
viewed
Dialysis was then performe
performed on the collected samples, in order
er to purify the
sample further, remove Imidazole from the sample, but mostly to cleave off the
His-tag
tag present on the protein. The cleavage of the His-tag
tag was achieved by the
addition of 500 mic
microliters of GST-TEV. The fractions with the most DPY-30
present were combined and then run over another Nickel Affinity
Chromatography column
column. The samples with protein were collected and run on a
second SDS polyacrylamide gel to again check purity (see Figures 4 and 5).
5) The
gel was stained using the above procedure.
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Figure 4: DPY-30
30 R54A His
His-trap Run 2. The R54A protein sample (lanes 1-8)
8)
after its second nickel chromatography run. There are considerably fewer
impurities present. The crude extract and protein marker were run alongside
the samples to use as reference points.
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Figure 5: DPY-30
30 L66A His
His-trap Run 2. The L66A protein
sample (lanes 1-12)
12) after its second nickel chromatography
run. There are considerably fewer impurities than after the
first run. The crude extract for the second run is a sample of
the protein after dialysis is completed.
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The fractions were combined and the sample was concentrated down to 5 or
less milliliters, if necessary. The concentration of the protein was measured
using the Nanodrop spectrophotometer and then the extinction coefficient
(0.397) was calculated using the NCBI website, which then led to the calculation
of the true concentration of the protein. The sample was then run on a size
exclusion chromatography column. The fractions were then analyzed using SDS
PAGE (see Figures 6 and 7) and the staining/destaining procedure used above.
Some samples were placed in the -80°C freezer, while another was used for
performing analysis.
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20
15
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PM 1 2 3 4 5

6

Figure 6: DPY-30 R54A Gel Filtration Run.
The R54A protein sample (lanes 1-6) after its
size exclusion chromatography run. The
sample is virtually impurity free.
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Figure 7: DPY
DPY-30 L66A Gel Filtration Run. The L66A
protein sample (lanes 1-8) after its size exclusion
chromatography run. Essentially all impurities have
been removed by this point.

Native Gel Assay, Sedimentation Velocity Analytical Ultracentrifugation, and [3H]
Methyltransferase Assay
The mutant protein’s binding ability with ASH2L was determined
ermined using
Native gel assays and Sedimentation Velocity Analytical Ultracentrifugation (SV
(
AUC). These technique
techniques tested the hypothesis that the mutated
ed Arginine (Arg54
or R54) was involved in DPY
DPY-30’s interaction with ASH2L. If it was, then the
ASH2L and DPY-30
30 should either not form a complex at all and will
wi remain two
separate proteinss or have a weakened interaction, as determined by SV AUC.
The Native gel was used to yield qualitative results by vi
visually
sually determining
whether or not that the two proteins were interacting as normal. The AUC was
used to yield quantitative results by measuring the sedimentation coefficient of
the proteins and protein complexes
complexes. The R54A mutant was then analyzed using

13

an enzymatic assay, so see what effect, if any, the mutant had on the
methyltransferase
ferase activity of the WRAD ccomplex. The mutant DPY-30
DPY
was
combined with the WDR5, RbBP5, and ASH2L and this complex was compared to
the wild-type WRAD complex. A radioactive methyl group donor (radioactive SS
adenosyl methionine, SAM) (see Figure 8) was used to measure the amount of
methylation that occurred.

Figure 8: S-adenosylmethionine (SAM). The methyl group (-CH
CH3)
on the Sulfur (S) is the methyl group that is transferred from one
1
molecule to another. The regular Hydrogens ( H) were replaced
3
with ( H), or Tritiums, which are radioactive. An enhancer
solution was then used so that the activity could be visualized.

Similar methods and techniques were used for the other mutant DPY-30
DPY
proteins that were generated: R76A, L65A, and L66A. The R76A and L65A
mutants were carried through to the phase where they were expressed and then
frozen as pellets in the -80°C
C freezer, while the L66A mutant was fully purified
and analyzed,, with the exception of using it in the enzymatic activity assay.
assay
Future experiments would revolve around inducing other singl
single
e amino acid or
maybe even multiple mutations in the DNA and repeating the methods used for
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the R54A site-directed mutagenesis. Other areas of research could include
determining the mutant’s effect on the activity of the MLL1 core complex and/or
what the structure of DPY-30 is while bound to ASH2L.
The R54A Mutant Negatively Affects DPY-30’s Interactions With ASH2L While the
L66A Mutant Does Not
The sequence alignment identified 13 completely conserved sites
between the DPY-30 homologs/DPY-30-like proteins (see Figure 15, Appendix A).
Based on the native gel assay and the AUC data, the R54A DPY-30 mutant was
still able to bind with wild-type ASH2L. The Native gel showed slight differences
between the lane with the wild-type DPY-30 and ASH2L (lane 3) and the lane
with the mutant DPY-30 and ASH2L (lane 5). There was a greater amount of free
ASH2L left in the lane with the mutant DPY-30 than in the lane with wild-type
DPY-30 (see Figure 9). This implies that the binding was weakened as a result of
the mutation.
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Wt DPY-30 +
Wt ASH2L

DPY-30 R54A +
Wt ASH2L

Wt DPY-30

DPY-30 R54A
Wt ASH2L

1

2

3

4

5

Figure 9: DPY-30 R54A Native
gel assay. Lanes, from left to
right – wild-type DPY-30 (lane
1), wild-type ASH2L (lane 2),
wild-type DPY-30 interacting
with wild-type ASH2L (lane 3),
mutant DPY-30 (lane 4), and
mutant DPY-30 interacting with
wild-type ASH2L (lane 5). In the
last lane, there is more unbound
ASH2L leftover with the mutant
DPY-30 than in the lane with the
wild-type DPY-30.
Concentrations of ASH2L, wildtype DPY-30, and mutant DPY30 were 0.5 milligrams/milliliter.
These results suggest that the
R54A mutant is still able to bind
with wild-type ASH2L but that
the interaction is weaker.

The AUC results showed that the mutant protein had a similar
sedimentation coefficient to the wild-type protein for its main peak, but there
were also additional peaks present for the mutant protein that were absent from
the wild-type protein (see Figure 10a). The peak that normally corresponds to
wild-type ASH2L binding with wild-type DPY-30 shifted when the R54A DPY-30
mutant was run on the AUC with wild-type ASH2L (see Figure 10b).
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A

1.0 mg/ml
0.6mg/ml
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5
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4
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1

0
Ash2L-DPY30(R54A)
(3.2 S*)

B
6
DPY30 (1.4 S*)

4

c(s)

Ash2L-DPY30 (wt)
(3.0 S*)

2
Ash2L

0
1

2

3

4

5

Sedimentation coefficient (S*)

Figure 10a (top): DPY-30 R54A SV AUC. The AUC data for the DPY-30 R54A mutant at three
different concentrations: 1.0 milligrams/milliliter, 0.6 milligrams/milliliter, and 0.2
milligrams/milliliter. The main peak for all three runs has a sedimentation coefficient of 1.3.
Wild-type DPY-30 has about the same sedimentation coefficient. The wild-type protein does
not have any additional peaks, however, as opposed to the mutant protein. These additional
peaks might be caused by other conformations of the protein, which were most likely brought
on by the mutation that was made. These results suggest that mutation affects DPY-30’s ability
to fold properly, which could result in multiple conformations.
Figure 10b (bottom): The AUC data for wild-type DPY-30 by itself, wild-type ASH2L by itself, wt
DPY-30 + wt ASH2L, and wt ASH2L + DPY-30 R54A. The concentration for all the proteins
analyzed was 0.5 milligrams/milliliter. The peak for the mutant complex has a different
sedimentation coefficient than the wild-type complex. This result backs up the result from the
native gel assay (above) suggesting that the mutant DPY-30 is still able to bind to wt ASH2L but
that the interaction is not quite the same as compared to the wild-type complex.

17

The enzymatic activity as
assay that was subsequently perfor
ormed revealed
that the WRAD
RAD complex with the mutant DPY
DPY30 was not
ot active with the H3
peptide (see Figure 11).

3

H
Figure 11: DPY
DPY-30 R54A Enzymatic activity assay. Left lane hass WRAD
complex with wild
wild-type DPY-30. Right lane has WRAD complex with mutant
DPY-30.
30. Wild
Wild-type complex shows activity with histone H3 peptide
ide while
mutant complex do
does not. Results suggest that DPY-30
30 does play a role in the
complex’s enzymatic functionality.

The results for the L66A mutant, on the other han
hand,
d, were not nearly as
noteworthy.. The Native gel did not appear to show any significant differences
between the mutant DPY
DPY-30-ASH2L complex (lane 5) and the wild-type
wild
DPY-30ASH2L complex (lane 3)
3).. This suggested that the binding was not affected by this
particular
cular mutation (see Figure 12).
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1

2

Wt
ASH2L

Wt DPY-30
Wt DPY
DPY-30 +
Wt ASH2L

3

4

5
DPY-30
L66A +
Wt
ASH2L

DPY-30 L66A

Figure 12: DPY-30
30 L66A Native
gel assay. Lanes, from
fro left to
right – wild-type
type DPY-30
DPY
(lane 1),
wild-type ASH2L (lane 2),
2) wildtype DPY-30
0 interacting with wildwild
type ASH2L (lane 3),
3) mutant DPY30 (lane 4),, and mutant DPY-30
DPY
interacting with wild-type
wild
ASH2L
(lane 5). There are about equal
amounts of ASH2L bound with the
mutant DPY-30 as there is with
the wild-type DPY-30.
30.
Concentrations of ASH2L, wildwild
type DPY-30,
30, and mutant DPY-30
DPY
were 0.5 milligrams/milliliter.
These results suggest that the
L66A mutant binds to ASH2L as
well as wild-type
type DPY-30.
DPY

This conclusion was confirmed by the AUC results, in which the mutant
DPY-30-wt
wt ASH2L complex had the same sedimentation coefficient as the wildwil
type complex (see Figure 13). Additionally, the mutant DPY-30
30 had about the
same sedimentation coefficient as the wild
wild-type protein (see Figures 14a-c).

Figure 13: DPY-30
DPY
L66A SV
AUC. AUC data for WildWild
type ASH2L + DPY-30
DPY
L66A
at three different
concentrations, 1.75μM,
3.5μM, and 7μM. All three
peaks are at 3.1 S*, which
is about the sedimentation
coefficient of wild-type
wild
DPY-30
30 + wild-type
wild
ASH2L.
This suggests that the
mutation has no effect on
DPY-30’s
30’s ability to bind to
ASH2L.
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A

B

C

Figure 14a (top): DPY-30 L66A SV AUC. AUC data for DPY-30 L66A, at 0.125mg/mL.
Figure 14b (middle): AUC data for DPY-30 L66A, at 0.25mg/mL.
Figure 14c (bottom): AUC data for DPY-30 L66A, at 0.5mg/mL. All three samples
have peaks at 1.31, which is about the sedimentation coefficient for wild-type DPY30. There are also no additional peaks of any significance present. This suggests
that the mutation has no effect on the conformation of the protein.

DISCUSSION
The identification of the conserved residues implied that they were of
some importance. If not, they would have been less likely to be conserved over
the course of evolution across different species. This led to the belief that
mutating one of them would have some negative effect on DPY-30’s ability to
dimerize and/or bind with ASH2L. The R54A mutation appears to be somewhat
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important regarding the binding sites between DPY-30 and ASH2L. This
mutation additionally seems to affect DPY-30’s ability to fold properly, as the
mutant by itself had an altered sedimentation coefficient than its wild-type
counterpart. One possible explanation is that the mutation caused different
conformations of the protein to form, such as an alternate dimer or perhaps
even a tetramer. Sedimentation coefficients are dependent upon both the mass
and shape/conformation of the molecule being analyzed. In this case, both
variables were changed, but the conformation probably had a greater effect than
the mass. The mutant DPY-30 also appears to affect the enzymatic activity of the
WRAD complex. The inactivity of the WRAD complex with the H3 peptide
suggests that DPY-30 might play an important role in the enzymatic activity of
this complex.
The L66A mutant, it was concluded, did not seem to play a significant
role, or any role, in either DPY-30’s ability to fold properly or DPY-30’s ability to
bind to ASH2L. There were no additional peaks present in the mutant AUC data,
suggesting that no alternate conformations of the protein were formed. The
difference in mass between the mutant and wild-type was also not enough on its
own to illicit a change in the sedimentation coefficient.
The results of these experiments illustrated that Arginine 54 was located
along the DPY-30 dimer interface as well as the DPY-30-ASH2L interface,
whereas Leucine 66 was not. This might explain the two differing results
between the mutants. Another explanation might be the nature of the
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substitution that was made in each mutant. Arginine is a large, positively
charged molecule while Alanine is a small, neutral, and hydrophobic molecule.
Leucine is a large molecule also, but is neutral and hydrophobic. If time had
permitted, an enzymatic assay would have been performed with the L66A
mutant, even though it most likely would not have shown any significant
difference in activity from the wild-type MLL complex. It would have also been
beneficial to also test the other two mutants that were made, L65A and R76A, to
see what kind of results these proteins yielded.
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Appendix A

Figure 15: Sequence Alignment of DPY-30
homologs. The 13 completely conserved amino
acids have a star beneath their column and are
boxed in.
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Appendix B
Buffer Preparation
50 mg/ml stock solution of Carbenicillin: 10mL doubly deionized water (ddH20) + 500mg
Carbenicillin
1x-Chloramphenicol (20mg/mL): 10mL Ethanol + 200mg 1x-Chloramphenicol
1M stock solution of IPTG: 10mL ddH20 + 2.3831g IPTG
Column Buffer (4L, pH 7.4): 50mM Tris (24.228g), 300mM NaCl (70.128g), 3mM DTT
(1.851036g), 30mM Imidazole (8.1696g) + ddH20
Elution Buffer (500mL, pH 7.4): 50mM Tris (3.0285g), 300mM NaCl (8.766g), 3mM DTT
(0.2313795g), 500mM Imidazole (17.02g) + ddH20
Lysis Buffer: 50mL of Column Buffer + 0.1mM Phenylmethanesulfonylfluoride (PMSF) +
1 Ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor cocktail tablet
Destain 1 (2L): 50% 100 proof Ethanol (1L) + 10% Acetic Acid (200mL) + ddH20
Destain 2 (2L): 5% 100 proof Ethanol (100mL) + 10% Acetic Acid (200mL) + ddH20
Buffer A (2L, pH 8.5): 25mM Tris-HCl (3.0285g) + 19.2mM Glycine (1.42633g)
Agarose gel (0.8%): 50mL Buffer A + 0.4g Agarose
LB (100mL): 3 pellets + ddH20
TBII (50mL): 2.5g TBII + ddH20
Coomassie Stain (2.5L): 7g Brilliant Blue R + 250mL Acetic Acid + 1125mL 100 proof
Ethanol + 1125mL ddH20
t-CEP Buffer (600mL, pH 7.5): 20mM Tris-Cl (1.45368g Tris) + 300mM NaCl (10.5192g) +
1μM ZnCl2 (6μL) + 1mM t-CEP (0.1770g) + ddH20
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Captsone Summary
The human version of the DPY-30 protein is homologous, or very closely
related, to the DPY-30 protein in Caenorhabditis elegans, along with other DPY30 homologous proteins in other organisms. This protein is involved in dosage
compensation of sex-linked or X-linked genes, balancing the levels of expression
between the sexes. The mechanism by which the balancing is carried out varies
from organism to organism. For example, in C. elegans, hermaphrodites are XX
and the transcript levels of the X-linked genes are cut in half. In Drosophila (fly),
the genes on the male’s (XY) X chromosome are transcribed at twice the rate of
the female’s (XX) genes. Transcription is the process of converting a DNA
sequence into the corresponding mRNA. In human females (XX), one of the X
chromosomes in each cell is inactivated at random. The inactivated X
chromosome becomes highly condensed, forming what is called a Barr body. If
DPY-30 is not functioning properly or the protein is absent from the organism,
this can lead to XX-lethality (death). Death is caused by the overdose of the
proteins encoded by the X chromosome genes. This protein is also involved in
developmental processes in animals that are XO. Some of these processes
include mating behavior, normal body size, correct tail morphology, and
coordinated movement.
In humans, DPY-30 forms a complex with four other proteins: MLL1,
WDR5, RbBP5, and ASH2L. This complex is responsible for methylating histones,
particularly histone H3 Lysine 4 (H3K4). Lysine is one of the twenty amino acids
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used as the building blocks for proteins. A histone is a protein that interacts with
DNA. There are 5 types of histones: H1, H2A, H2B, H3, and H4. The last four
histones form an octamer (2 copies of each individual histone) that DNA strands
wrap around to help condense them. This is called a nucleosome. H1 serves as a
linker molecule between nucleosomes. Methylation refers to adding a methyl
group (-CH3) to a molecule. Methylation of H3K4 promotes transcription of
genes, some of which are necessary for the organism’s survival. Methylation of
DNA is an example of epigenetic regulation, meaning it can bring about changes
in the expression of certain genes without altering the DNA sequence of the
organism. Epigenetics refers to any heritable change in gene expression, meiotic
and/or mitotic, that is not actually coded for in the DNA sequence of an
organism. These changes are heritable because they can be passed on to the
offspring of an organism. Similar complexes are found in other organisms. The
fact that these proteins are conserved across species indicates how important
they are. Within the complex itself, DPY-30 binds to ASH2L. The amino acids
responsible for this interaction, however, remain unknown. The purpose of this
project is to identify which amino acids are responsible for the binding between
DPY-30 and ASH2L.
A further extension of this project is its potential anticancer applications.
The MLL1 gene had been found to break apart and rejoin with either other MLL1
genes or other genes. This leads to the production of abnormal fusion proteins.
These fusion proteins lead to improper activity of MLL1. When MLL1 is activated
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improperly and forms the complex, it can lead to the development of Acute
Lymphoblastic Leukemia (ALL). It is thought that if the complex were to be
disrupted and broken apart or prevented from forming, the cancerous cell would
stop proliferating and die. If the amino acids responsible for the DPY-30 and
ASH2L binding were identified, a drug or peptide, which is a chain of amino acids,
could be designed to bind to DPY-30 or ASH2L, preventing it from completing
formation of the MLL1 Core Complex.
The first step in this experiment was to compare DPY-30 homologs from
different species, to see if any amino acid residues were either completely
conserved or mostly conserved. These conserved residues, or amino acids,
would most likely be very important to DPY-30’s ability to function. A conserved
residue is one that is the same in all or most of the different species when
looking at a similar protein in those different organisms. Once the conserved
residues were identified, one was selected to change, Arginine (R) 54. It was
changed to an Alanine (A). Three other single amino acid mutations were made:
Arginine (R) 76, Leucine (L) 66, and Leucine (L) 65. All three were changed to
Alanines. Arginine, Leucine, and Alanine are three more of the twenty amino
acids. Once primers, short segments of DNA, with the correct mutation were
made, the DNA sequence was put through Polymerase Chain Reaction (PCR) and
transformed into E. coli cells. PCR amplifies a specific segment of DNA, while a
transformation is the term used when foreign DNA is being introduced into an
organism. The DNA was extracted, sequenced, and transformed into another E.
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coli strain. The DNA was extracted by breaking open the cells. Sequencing refers
to determining the exact sequence of a DNA segment to make sure it is correct.
In this case, the DNA was being checked for the presence of the correct
mutation, while the rest of the sequence was wild-type, or not mutated. A large
culture of bacteria was grown, expression of protein was induced, the cells were
lysed or broken open, and the protein was collected. Once the mutant protein
was purified, it was subjected to multiple tests to determine its binding affinity
for ASH2L. The purification served to isolate the mutant DPY-30 protein from all
the other proteins present in the cells, so that experiments could be run on a
fairly pure sample. Otherwise, these other proteins might interfere with the
results, making them unreliable and difficult to interpret. For the R54A mutant,
the binding interactions were weakened, but not completely inhibited. For the
L66A mutant, there was no measurable effect on the binding interactions and
the proteins interacted with each other as they normally do. It was concluded
that Arginine 54 was a much more important residue than Leucine 66, as far as
binding affinity was concerned.
It would have been interesting to examine the results from the other two
mutants that were generated, if there had been time to test them. It certainly
seems that R54 is one of the amino acids involved in the binding of ASH2L by
DPY-30, while L66 is not. If time had permitted testing of the other two
mutations, as well as making additional mutations, more of the amino acids
responsible for the binding might have been identified. This could have
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potentially led to complete identification of all the necessary amino acids, which
in turn could have led to total inhibition of binding between the two proteins.
This might have been achieved by changing all the important amino acids into
Alanines or just deleting the important amino acids. If complete inhibition of
binding was achieved, a peptide or drug with the appropriate sequence could
have been designed and tested to see how well it interacted with DPY-30 and,
subsequently, blocked ASH2L from binding with DPY-30.

